Glaukos (GKOS) Projected to Release Earnings on Wednesday

Glaukos (NYSE:GKOS) is projected to release its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect the company to post earnings of ($0.0964) per share and revenue of $168.04 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 4:30 PM ET.

Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.07. The company had revenue of $185.61 million for the quarter, compared to the consensus estimate of $150.93 million. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%. The firm’s revenue for the quarter was up 49.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.24) earnings per share. On average, analysts expect Glaukos to post ($0.32) EPS for the current fiscal year and $0.55 EPS for the next fiscal year.

Glaukos Stock Performance

NYSE:GKOS opened at $178.27 on Tuesday. The stock has a 50 day simple moving average of $171.35 and a 200 day simple moving average of $139.19. The stock has a market cap of $10.51 billion, a P/E ratio of -54.85 and a beta of 0.69. Glaukos has a 1-year low of $73.16 and a 1-year high of $191.62. The company has a current ratio of 5.04, a quick ratio of 4.46 and a debt-to-equity ratio of 0.10.

Insider Buying and Selling

In other Glaukos news, CFO Alex R. Thurman sold 20,000 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $180.13, for a total value of $3,602,600.00. Following the transaction, the chief financial officer directly owned 43,906 shares of the company’s stock, valued at $7,908,787.78. This trade represents a 31.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Leana Wen sold 525 shares of the firm’s stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $167.63, for a total transaction of $88,005.75. Following the completion of the transaction, the director directly owned 21,092 shares in the company, valued at approximately $3,535,651.96. This represents a 2.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 83,025 shares of company stock worth $14,950,006 over the last three months. Company insiders own 5.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on GKOS shares. BTIG Research lifted their target price on Glaukos from $202.00 to $205.00 and gave the stock a “buy” rating in a report on Monday, October 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a research note on Thursday, October 15th. Piper Sandler reaffirmed an “overweight” rating and set a $195.00 price target (up from $165.00) on shares of Glaukos in a research report on Thursday, July 30th. Stifel Nicolaus lifted their price objective on shares of Glaukos from $175.00 to $190.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Finally, Wells Fargo & Company boosted their price objective on shares of Glaukos from $138.00 to $178.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Glaukos has an average rating of “Moderate Buy” and an average target price of $181.43.

About Glaukos

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company’s principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.